Lung cancer is the number one cause of cancer-related death among both men and women worldwide.
well-known oncogenic lncRNA that is up-regulated in several cancers. 11 The lncRNA linc00665 has recently been represented as an oncogenic factor in LUAD. 12 However, there are hundreds of lncRNAs that their exact roles in different cancers are yet to be discovered and/or experimentally validated. RAB6C-AS1, for instance, is a poorly known lncRNA that is presented as a potential candidate biomarker for prostate and brain cancers but its implications in the carcinogenesis of these cancers are not still neither computationally nor experimentally examined and validated. 13 LncRNAs are also involved in the tumourigenesis and progression of lung cancer through aberrant regulation of gene expression at the transcriptomic, epigenomic and genomic levels. 14 Additionally, epigenetic and RNA deregulations are considered as a potential hallmark of LUAD. 15 Altogether, discovering the functional roles of lncRNAs in LUAD would greatly enhance our knowledge of the aetiology of LUAD and lead to the advent of novel promising biomarkers and drug targets for this deadly disease.
As lncRNAs play essential roles in the progression of different cancers, they have the potential to be used as diagnostic and prognostic biomarkers. 16 Also, the presence of several circulating transcripts has been reported in the plasma and serum of cancer patients which could be used for diagnostic purposes. 17 Moreover, different circulatory non-coding RNAs (ncRNAs) including lncRNAs are being constantly represented as biomarkers for cancer diagnosis, prognosis and monitoring of treatment response. 5, 18 Thus, lncRNAs are potential factors for the prediction of OS and disease-free survival (DFS) periods of cancer patients. Today, lncRNAs are being regarded as potential diagnostic factors and therapeutic targets for NSCLC. 19 The lncRNA LINC00578, as an example, is represented as a promising biomarker and therapeutic target for LUAD. 20 In another study, TG et al introduced three lncRNAs including HCP5, SNHG12 and LINC00472 as potential biomarkers for LUAD management. 21 Also, several lncRNAs such as LHFPL3-AS2, LINC01105, LINC00092, LINC00908 and FAM83A-AS1 have been reported as prognostic factors for LUAD. 22 Furthermore, the diagnostic value of circulating lncRNAs as plasma signatures for the early detection of lung cancer has been confirmed. 23 A growing number of computational models are being constantly developed for the identification of lncRNA-disease associations and characterization of functional roles of lncRNAs in diseases including lung cancer. KATZLDA, as an example, is a robust computational model for the prediction of lncRNA-disease associations. 24 In another study, Chen et al proposed a kind of top-down model. They assumed that similar diseases tend to be associated with functionally similar lncRNAs and accordingly, developed a computational model named LRLSLDA. 25 Generally speaking, identification of lncRNAdisease associations is achieved based on two different approaches;
using known lncRNA-disease associations, as in machine learningbased and network-based models, or using models based on the known disease-related genes/miRNAs. Functional similarity calculation method, which is based on the assumption that functionally similar lncRNAs are associated with similar diseases, is commonly applied in both of the aforementioned approaches but usually in combination with other methods. 26 Various information resources are used for the calculation of lncRNA functional similarity which could be summarized into four categories: lncRNA expression similarity, GO term-based lncRNA functional similarity, miRNA/mRNAlncRNA interaction-based functional similarity and lncRNA-disease association-based functional similarity. 27 In the current study, a GO term-based lncRNA functional similarity method was used to functionally interrogate the lncRNA-LUAD associations. In the context of the prediction of functional roles of lncRNAs in diseases, several computational models have thus far been proposed that could be classified into four major categories, including gene coexpressionbased models, lncRNA-miRNA/mRNA/protein interaction-based models, sequence alignment-based models and integrative featuresbased models which incorporates sequence-derived and experimental features of lncRNAs. 27 In this study, we applied a coexpression-based model for the prediction of functional roles of lncRNAs in LUAD. It is frequently reported that lncRNAs are differentially expressed (DE) in cancer tissues. 28 Also, according to the guilt by association principle, if a gene shows an expression correlation with the expression profiles of a set of genes involved in a specific function, that gene is possibly involved in the same function. 29 Therefore, identification of the coexpressed genes (CEGs) of DE-lncRNAs can help functional annotation of lncRNAs in cancer. Moreover, CEGs can have common regulatory sequences and might be interacting partners of the same complex and/or involve in the same pathway. 30 Actually, dysregulated lncRNAs interact with other macromolecules and consequently drive various cancer manifestations. 31 Hence, identification of the CEGs of DE-lncRNAs in cancer assists in the characterization of oncogenic or tumour suppressive functions of lncRNAs and recognition of pathways they are involved in. This is a common methodology that can be used for the functional annotation of poorly known genes in the context of different diseases including cancer. 32 There are several notable variances in the gene expression profile and molecular features between LUSC and LUAD and consequently different therapeutic strategies and regiments are administrated to these two major subtypes of NSCLC. 33 Thus, NSCLC studies should precisely target either LUAD or LUSC so as to get more specific results. In this study, we systematically analysed the prognostic value of lncRNAs for LUAD and annotated their functional roles using a bioinformatic and systems biology approach. A schematic outline of the implemented methodology is given in Figure 1 .
| ME THODS

| Data preparation
All of The Cancer Genome Atlas (TCGA) LUAD DE-lncRNAs (1 < |Log2FC|; adjusted P-value (adjp) < 0.05) were retrieved from the circlncRNAnet (Table S1 ). 34 The circlncRNAnet is an integrated webbased resource for mapping functional networks of long or circular forms of ncRNAs. TCGA LUAD is one of the projects conducted by TCGA Research Network and comprises 483 LUAD tumour samples and 59 normal lung samples. Also, all TCGA LUAD DEGs were obtained from GEPIA (Table S2) . 35 GEPIA is a web server specialized for analysing the RNA-seq data of 9736 tumours and 8587 normal samples from the TCGA and the GTEx projects. In the context of the differential expression analysis of genes in LUAD, GEPIA has added 288 normal lung samples from GTEx projects to the normal samples of TCGA LUAD so as to make a higher balance between the number of normal and cancer samples. Then, common DE-lncRNAs between circlncRNAnet and GEPIA with the same expression dysregulation (either over-or underexpression) in both databases were selected.
Moreover, a total of six plasma RNA-seq data samples, including three normal and three NSCLC plasma samples, were retrieved from the PRJNA286036 study at the European Nucleotide Archive and analysed using an Australian Galaxy server (GVL QLD, GVL 4.0.1;
https ://galaxy-qld.genome.edu.au/galaxy). 
| Data filtration
All of the prepared data were filtered so as to make our downstream analyses more specific. First, the list of lncRNAs selected from the intersection of data retrieved from circlncRNAnet and GEPIA databases was combined with the list of lncRNAs outputted from the RNA-seq data analysis. This combined list was named as the gene library (gene library = (circlncRNAnet DE-lncRNAs ⋂ GEPIA DEGs) ⋃ (NSCLC plasma DE-lncRNAs ⋂ LUAD altered/DE-lncRNAs)). Then, the lncRNAs without RefSeq sequences in the gene library were filtered out in order to lay a firm foundation for our downstream analyses. To this purpose, a list of all RefSeq lncRNAs was retrieved from HGNC BioMart (Table S3) 
| Survival analysis
Prognostic value of those RefSeq lncRNAs that remained in the last step of the data filtration process was investigated using the GEPIA web server. To this end, the prognostic value of all of the 45 was used to perform a multivariate Cox regression analysis on a LUAD microarray study (GSE31210). In this step, a microarray dataset rather than an RNA-Seq one was used to obtain more reliable results.
| Coexpression analysis
The coexpression analysis was done for each lncRNA independently. Different resources of TCGA LUAD processed data were integrated in order to identify high-confident CEGs. To this purpose, first, all of the significantly CEGs with each lncRNA were retrieved from both circlncRNAnet and GEPIA databases and their shared genes were outputted. Then, the intersection of CEGs with the list of all LUAD DEGs was queried ((circlncRNAnet CEGs ⋂ GEPIA CEGs) ⋂ GEPIA DEGs) so as to separate differentially expressed CEGs (DECEGs) (Table S4) . Finally, the coexpression networks of lncRNAs with one another and with other DEGs were reconstructed using Cytoscape v3.5.1.
46
| Functional analysis
A coexpression-based model was applied for the prediction of functional roles of lncRNAs in LUAD. First, the DECEGs of each LAProLncR were used to perform a gene set enrichment analysis for gene ontology-biological process (GO-BP) terms via Enrichr web server. 47, 48 It should 
| Clinicopathological and demographic analysis
The differential expression of LAProLncRs among different LUAD stages was analysed using the GEPIA web server. Also, the impact of
The lncRNA-GO-BP association network. The yellow nodes represent LAProLncRs. The intensity of pink node colour indicates the betweenness centrality score; stronger pink colour indicates higher betweenness centrality score. The node height is proportional to node degree; Bigger node indicates higher node degree. The edge colour is representative of the source database of predicted GO term and the reference tissue type. Please refer to Table 2 for finding the description of GO IDs. The network was reconstructed using the Cytoscape software smoking habit and gender on the expression of prognostic lncRNAs in LUAD was investigated using the Lung Cancer Explorer (http://lce.
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biohpc.swmed.edu/lungc ancer ). Lung Cancer Explorer is an online
database that provides the exploration of gene expression data from several public lung cancer datasets.
| Statistical and topological analysis
All of the statistical analyses, except Cox regression analysis, were done using R statistical software (R Development Core Team (2014), freely available at http://www.r-proje ct.org). The multivariate Cox regression analysis was done by the Kaplan-Meier plotter web server. The Pearson correlation coefficient (R)>0.3 was considered as the significant threshold throughout the study. Also, the P-value < 0.05 was considered statistically significant in all of the analyses. In the context of graph topology, two network metrics including betweenness centrality (a measure of node centrality based on shortest paths) and degree (the number of edges incident to each node) were coincidently employed to determine the hub nodes, whenever possible.
| RE SULTS
| Selection of 168 lncRNAs as the gene library
After filtration of the TCGA LUAD DE-lncRNAs, only 164 lncRNAs remained. Also, RNA-seq data analysis resulted in 109 circulating lncRNAs with significant differential abundance (2 < |Log2FC|, adjp < 0.05) in NSCLC plasma samples compared with normal ones (Table S5) .
Interestingly, all 109 lncRNAs had lower abundance in NSCLC plasma samples compared with normal samples. Filtration of these 109 lncRNAs through circlncRNAnet and cBioPortal databases indicated that four of the 109 circulating lncRNAs were significantly amplified/ overexpressed in TCGA LUAD samples (Data not shown). Altogether, 168 lncRNAs were selected for downstream analyses (Table S6 ).
| Presentation of 19 lncRNAs as candidate LUAD biomarkers
Among all lncRNAs in our gene library, only 62 lncRNAs came out as RefSeq lncRNAs after filtration through HGNC RefSeq lncRNAs (Table S7 ). Subsequently, survival analyses using the GEPIA web server demonstrated that 19 of the 62 RefSeq lncRNAs had significant prognostic values (Logrank test P-value < 0.05) for LUAD (Table 1) . Remarkably, one of these lncRNAs, namely SNHG6, was of the lncRNAs with differential abundance between plasma samples of NSCLC patients and healthy controls. Also, Kaplan-Meier plots illustrated that the association of these 19 lncRNAs with OS/DFS of patients is in accordance with the dysregulation of these lncRNAs in TCGA LUAD cancer samples (Figure 2 and Figure S1 ). Actually, while down-regulated lncRNAs had higher expression levels in patients with higher percentages of OS/DFS, up-regulated lncRNAs had lower expression levels in those patients. Furthermore, the expression analysis of these lncRNAs using the GEPIA web server demonstrated obvious differences in the expression of these 19 lncRNAs between normal and cancer samples (Figure 3 ).
| LAProLncRs are coexpressed with several other genes
The coexpression analysis of lncRNAs indicated that they were sig- 
| LAProLncRs are involved in several regulatory biological processes
The gene set enrichment analysis of the DECEGs of LAProLncRs indicated that these lncRNAs might be involved in several regulatory biological processes including cancer-related ones ( Figure 5 ; Table 2; Table   S8 ). As depicted in the lncRNA-GO-BP network, some lncRNAs and their associated GO terms were grouped in modules and might work in common biological processes. While C8orf34-AS1 and LINC00467 in (Table 3 and Figure S2 ).
| The expression of some of the LAProLncRs is associated with clinicopathological and demographic features
The analyses demonstrated that the expression of nine of the 19
LAProLncRs was significantly associated (P-value < 0.05) with different stages of LUAD ( Figure 6 ). Also, the violin plots in Figure 6 indicated that the association of these nine lncRNAs with different stages of LUAD is in accordance with the dysregulation of these lncRNAs in TCGA LUAD cancer samples; while up-regulated lncRNAs usually (Table 4 ).
| D ISCUSS I ON AND CON CLUS I ON
The aim of this investigation was to systematically examine the di- LAProLncRs including ADAMTS9-AS2, 51 56 in LUAD has been previously demonstrated. Though, the prognostic value of most of these lncRNAs for LUAD patients has not been evaluated. Similarly, the differential abundance of lncRNAs in the plasma of normal and LUAD specimens, which could be used as signatures for diagnosis and prognosis of LUAD, has not yet been examined. Altogether, the detection and characterization of
LAProLncRs could help early diagnosis, prognosis and treatment of patients with this deadly disease. In this study, we addressed all of the above issues.
Circulating lncRNAs have recently emerged as novel cancer biomarkers for diagnostic and prognostic purposes. For instance, the circulating lncRNAs NEAT1, ANRIL and SPRY4-IT1 have been suggested as new diagnostic biomarkers for NSCLC. 5 It has been reported that the dysregulation of lncRNAs in plasma is in accordance with their dysregulation in the source tumour tissue. 16 Thus, according to our RNA-Seq data analysis, dysregulated lncRNAs in NSCLC plasma samples could be used for diagnostic purposes and might play important roles in NSCLC development. However, there is a delicate point that is yet ignored regarding the abun- (Table 5) 
TA B L E 4 (Continued)
insights into the functional roles of LAProLncRs in LUAD tumourigenesis. In addition to hub GO-BP terms, the shared terms between LUAD and normal lung tissues (blue edges in Figure 5 ) should also be considered with a higher priority in future studies. 
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